BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 22, 2003
View Archived Issues
Vertex, GSK Receive Approval For Flexible HIV Drug Lexiva
Vertex Pharmaceuticals Inc. and partner GlaxoSmithKline plc won FDA approval of Lexiva, an HIV protease inhibitor that can be dosed once or twice daily, with or without food and water restrictions. (BioWorld Today)
Read More
Cypress Bioscience Begins Milnacipran Phase III Trial
Read More
Cephalon's Provigil Receives Approval For Expanded Label
Read More
Biospect Raises $27M In Series A Round; Diagnostics First Focus
Read More
Other News To Note
Read More
Appointments And Advancements
Read More